# SLV-324

Source: https://onco.cc/drugs/slv-324/  
OnCo record `slv-324` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SLV-324 is an experimental antibody-drug conjugate from Solve Therapeutics, in phase 1 trials for metastatic solid tumours.

## Summary

SLV-324 is an antibody-drug conjugate from Solve Therapeutics. An antibody-drug conjugate combining a selective targeting antibody, the CloakLink linker and a potent cytotoxic payload, aimed at a membrane receptor protein on solid tumours that the company has not named (distinct from SLV-154's). Its furthest stage is phase 1, for metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07108114 recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: SLV-324
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate combining a selective targeting antibody, the CloakLink linker and a potent cytotoxic payload, aimed at a membrane receptor protein on solid tumours that the company has not named (distinct from SLV-154's).

## Sources

- Solve Therapeutics: solvetx.com: https://solvetx.com/
- Solve Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07108114
- ClinicalTrials.gov: trials of SLV-324: https://clinicaltrials.gov/search?intr=SLV-324

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Solve Therapeutics](https://onco.cc/companies/solve-therapeutics/)
- trials: [SLV-324 Treatment of Metastatic Solid Tumors](https://onco.cc/trials/nct07108114/)

---
JSON: https://onco.cc/api/v1/entities/slv-324.json